Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Holman

Showing results (651-660 of 716) with videos related to

Pageof 72
Sort By:
Heart (British Cardiac Society)|November 7, 2007
Triplane tissue Doppler imaging: a novel three-dimensional imaging modality that predicts reverse left ventricular remodelling after cardiac resynchronisation therapyN R Van de Veire, C-M Yu, N Ajmone-Marsan, et al.
Scientific Reports|November 23, 2022
Protein biomarkers of cardiac remodeling and inflammation associated with HFpEF and incident eventsJessica A Regan, Lauren K Truby, Usman A Tahir, et al.
Circulation|June 20, 2017
Secondary Prevention of Cardiovascular Disease in Patients With Type 2 Diabetes Mellitus: International Insights From the TECOS Trial (Trial Evaluating Cardiovascular Outcomes With Sitagliptin)Neha J Pagidipati, Ann Marie Navar, Karen S Pieper, et al.
The Lancet. Diabetes & Endocrinology|December 10, 2017
Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysisM Angelyn Bethel, Rishi A Patel, Peter Merrill, et al.
Redox Biology|October 30, 2020
Resolving the paradox of ferroptotic cell death: Ferrostatin-1 binds to 15LOX/PEBP1 complex, suppresses generation of peroxidized ETE-PE, and protects against ferroptosisTamil S Anthonymuthu, Yulia Y Tyurina, Wan-Yang Sun, et al.
Diabetes Care|November 24, 2019
Microvascular and Cardiovascular Outcomes According to Renal Function in Patients Treated With Once-Weekly Exenatide: Insights From the EXSCEL TrialM Angelyn Bethel, Robert J Mentz, Peter Merrill, et al.
Diabetologia|August 6, 2009
Intensive glucose control and macrovascular outcomes in type 2 diabetes, F M Turnbull, C Abraira, et al.
Analytical Chemistry|September 21, 2017
Development of a Cigarette Tobacco Filler Standard Reference MaterialLane C Sander, Jeanita S Pritchett, Yasmine C Daniels, et al.
American Heart Journal|November 2, 2013
Incidence of atrial fibrillation in a population with impaired glucose tolerance: the contribution of glucose metabolism and other risk factors. A post hoc analysis of the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research trialRoberto Latini, Lidia Staszewsky, Jie-Lena Sun, et al.
Diabetes/Metabolism Research and Reviews|March 7, 2023
Association of osteocalcin, osteoprotegerin, and osteopontin with cardiovascular disease and retinopathy in type 2 diabetesErnesto Maddaloni, Lucia Coraggio, Rocco Amendolara, et al.
Pageof 72

Showing results (651-660 of 716) with videos related to

Sort By:
Pageof 72
Heart (British Cardiac Society)|November 7, 2007
Triplane tissue Doppler imaging: a novel three-dimensional imaging modality that predicts reverse left ventricular remodelling after cardiac resynchronisation therapyN R Van de Veire, C-M Yu, N Ajmone-Marsan, et al.
Scientific Reports|November 23, 2022
Protein biomarkers of cardiac remodeling and inflammation associated with HFpEF and incident eventsJessica A Regan, Lauren K Truby, Usman A Tahir, et al.
Circulation|June 20, 2017
Secondary Prevention of Cardiovascular Disease in Patients With Type 2 Diabetes Mellitus: International Insights From the TECOS Trial (Trial Evaluating Cardiovascular Outcomes With Sitagliptin)Neha J Pagidipati, Ann Marie Navar, Karen S Pieper, et al.
The Lancet. Diabetes & Endocrinology|December 10, 2017
Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysisM Angelyn Bethel, Rishi A Patel, Peter Merrill, et al.
Redox Biology|October 30, 2020
Resolving the paradox of ferroptotic cell death: Ferrostatin-1 binds to 15LOX/PEBP1 complex, suppresses generation of peroxidized ETE-PE, and protects against ferroptosisTamil S Anthonymuthu, Yulia Y Tyurina, Wan-Yang Sun, et al.
Diabetes Care|November 24, 2019
Microvascular and Cardiovascular Outcomes According to Renal Function in Patients Treated With Once-Weekly Exenatide: Insights From the EXSCEL TrialM Angelyn Bethel, Robert J Mentz, Peter Merrill, et al.
Diabetologia|August 6, 2009
Intensive glucose control and macrovascular outcomes in type 2 diabetes, F M Turnbull, C Abraira, et al.
Analytical Chemistry|September 21, 2017
Development of a Cigarette Tobacco Filler Standard Reference MaterialLane C Sander, Jeanita S Pritchett, Yasmine C Daniels, et al.
American Heart Journal|November 2, 2013
Incidence of atrial fibrillation in a population with impaired glucose tolerance: the contribution of glucose metabolism and other risk factors. A post hoc analysis of the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research trialRoberto Latini, Lidia Staszewsky, Jie-Lena Sun, et al.
Diabetes/Metabolism Research and Reviews|March 7, 2023
Association of osteocalcin, osteoprotegerin, and osteopontin with cardiovascular disease and retinopathy in type 2 diabetesErnesto Maddaloni, Lucia Coraggio, Rocco Amendolara, et al.
Pageof 72